AMENDMENTS TO THE CLAIMS

Docket No.: 1209-0149PUS1

Art Unit: 1793

(Previously Presented) A chemically bonded biomaterial element comprising:
an inorganic cement, exhibiting minimal dimensional changes upon hardening and long-time use, improved mechanical properties and improved translucency;

and added inert filler particles, wherein

the biomaterial element has a micro-structure to meet an algorithm, which is-defined by a formula:

$$\lambda = \frac{d * (1 - V_F)}{(V_F)}$$

where λ is the distance between filler particles of mean size d, and V_F is the volume content of non-reacted cement and the added inert filler particles, and where $\lambda \leq 10~\mu m$, and wherein the added inert filler particles have a particle size below 5 μm , and wherein the added inert filler particles consist of glass particles, apatites, brucite and/or bohmite.

- 2. (Previously Presented) The biomaterial element according to claim 1, wherein $\lambda \leq 8$ µm.
- 3. (Previously Presented) The biomaterial element according to claim 1, wherein V_{F} is less than 50 %.

2 GMM/TK:kml

Docket No.: 1209-0149PUS1 Amendment in Response to Final Office Action dated April 24, 2008 Art Unit: 1793

4. (Previously Presented) The biomaterial element according to claim 1, wherein it exerts a pressure or tensile force of < 5 MPa on a surrounding volume.

5. (Currently Amended) The biomaterial element according to claim 1, wherein the inorganic cement comprises Ca-aluminate, Casilicate, and or Ca-phosphate, or a mixture thereof.

6. (Previously Presented) A biomaterial element according to claim 1, wherein the inorganic cement comprises CaO-Al₂O₃ system, and a particle size of formed hydrates of these phases is below 3 µm.

7. (Previously Presented) The biomaterial element according to claim 1, wherein the biomaterial element further comprises an organic phase of polyacrylates and/or polycarbonates at a volume content of less than 5 %.

8-9. (Cancelled)

10. (Previously Presented) The biomaterial element according to claim 1, wherein it comprises in-situ formed apatite that separates the formed hydrates of the main system.

Docket No.: 1209-0149PUS1

Art Unit: 1793

11. (Previously Presented) The biomaterial element according to claim 1, wherein a total porosity is below 10 %, where at least 90% of the pores are minipores having a diameter below 0.5 µm.

- 12. (Previously Presented) The biomaterial element according to claim 1, wherein it is a dental material.
- 13. (Currently Amended) The biomaterial element according to claim 1, wherein the biomaterial element contains an orthopaedic orthopedic material or a chemically bonded bone cement.
- 14. (Currently Amended) The biomaterial element according to claim 1, wherein it is a component, or is in granule form, or in a carrier material for drug delivery.
 - 15. (Cancelled)
- 16. (Previously Presented) The biomaterial element according to claim 1, wherein $\lambda \leq 4$ µm.
- 17. (Previously Presented) The biomaterial element according to claim 1, wherein $\lambda \leq 2$ μm .

Docket No.: 1209-0149PUS1

Art Unit: 1793

18. (Previously Presented) The biomaterial element according to claim 1, wherein V_F is

5-45 %.

19. (Previously Presented) The biomaterial element according to claim 1, wherein V_F is

15-35 %.

20. (Previously Presented) The biomaterial element according to claim 1, wherein it

exerts a pressure or tensile force of < 2 MPa on a surrounding volume.

21. (Previously Presented) The biomaterial element according to claim 1, wherein it

exerts a pressure or tensile force of < 1 MPa on a surrounding volume.

22. (Currently Amended) The biomaterial element according to claim 6, wherein the

CaO-Al₂O₃ system contains at least one selected from is CaO₃ (CaO)₃Al₂O₃, (CaO)₁₂(Al₂O₃)₇,

CaOAl₂O₃, (CaO)(Al₂O₃)₂, (CaO)(Al₂O₃)₆, or CaO, pure Al₂O₃ or and a mixture thereof.

23. (Previously Presented) The biomaterial element according to claim 6, wherein a main

phase of the CaO-Al₂O₃ system is CaOAl₂O₃ or (CaO)(Al₂O₃)₂.

24. (Previously Presented) The biomaterial element according to claim 6, wherein a main

phase of the CaO-Al₂O₃ system is CaOAl₂O₃.

Amendment in Response to Final Office Action dated April 24, 2008

25. (Previously Presented) The biomaterial element according to claim 6, wherein a

particle size of formed hydrates of these phases is below 1 µm.

26. (Previously Presented) The biomaterial element according to claim 6, wherein a

particle size of formed hydrates of these phases is below 0.5 µm.

27. (Previously Presented) The biomaterial element according to claim 1, wherein added

inert filler particles have a particle size below 2 µm.

28. (Previously Presented) The biomaterial element according to claim 1, wherein a total

porosity is below 5 %, distributed on minipores having a diameter below 0.1 µm, to an extent of

at least 90 % of the total porosity.

29. (Previously Presented) A biomaterial element according to claim 12, wherein the

dental material is a dental filling material or a root filling material.

30. (New) The biomaterial element according to claim 1, wherein it is a carrier material

for drug delivery.

GMM/TK:kml

Docket No.: 1209-0149PUS1

Art Unit: 1793

6